Cargando…
Comparison of Glycemic Excursion in Patients with New Onset Type 2 Diabetes Mellitus before and after Treatment with Repaglinide
Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increasing seriously. Repaglinide is a glucose reducing agent that predominantly reduces post-prandial glucose. Continuous glucose monitoring system (CGMS) monitors blood glucose excursions over a 3-day period. CGMS c...
Autores principales: | Hezarkhani, Sharabeh, Bonakdaran, Shokufeh, Rajabian, Reza, Shahini, Najmeh, Marjani, Abdoljalal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601336/ https://www.ncbi.nlm.nih.gov/pubmed/23526382 http://dx.doi.org/10.2174/1874091X01307010019 |
Ejemplares similares
-
Age Related Metabolic Syndrome Among Hemodialysis Patients in Gorgan, Iran
por: Marjani, Abdoljalal, et al.
Publicado: (2013) -
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021) -
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
por: Ma, J., et al.
Publicado: (2014) -
Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose
por: Kasthuri, Selvam, et al.
Publicado: (2021) -
Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2014)